Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kebuzone is a nonsteroidal anti-inflammatory drug (NSAID) of the pyrazolidinedione class, chemically related to phenylbutazone. It is primarily used for the treatment of inflammatory conditions such as thrombophlebitis and rheumatoid arthritis. Kebuzone acts mainly by inhibiting cyclooxygenase (COX) and lipoxygenase enzymes, thereby reducing the synthesis of prostaglandins and leukotrienes involved in inflammation via the arachidonic acid pathway. The drug has a long elimination half-life (70–100 hours), is excreted renally, and can be administered orally or intramuscularly. Its use has been associated with adverse effects including allergic reactions, gastrotoxicity, nephrotoxicity, local tissue necrosis at injection sites, and liver damage[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kebuzone.